Overexpression of 11beta-hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients

Overview

Journal Obes Surg

Date 2009 Aug 20

PMID 19690925

Citations 23

Authors

Rene Baudrand

Cristian A Carvajal

Arnoldo Riquelme

Mauricio Morales

Nancy Solis

Margarita Pizarro

Alex Escalona

Camilo Boza

Gustavo Perez

Angelica Dominguez

Marco Arrese

Carlos E Fardella

Affiliations

Soon will be listed here.

Abstract

Background: The enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes intracellular glucocorticoid reactivation by conversion of cortisone to cortisol in different tissues and have been implicated in several metabolic disorders associated with obesity. The aim of this study was to evaluate the 11beta-HSD1 expression in liver, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) in morbidly obese patients undergoing bariatric surgery and its correlations with clinical, anthropometric, and biochemical variables.

Methods: A prospective study was conducted over a 27-month period. Hepatic, VAT, and SAT samples were obtained at the time of surgery. 11beta-HSD1 and 18S gene expression was measured using real-time quantitative reverse transcriptase-polymerase chain reaction.

Results: Forty nine patients met the inclusion criteria [mean age: 42.2 +/- 10 years, body mass index (BMI): 42 +/- 6 kg/m(2), 71% women and 63% with metabolic syndrome (MS)]. 11beta-HSD1 mRNA levels were higher in liver than fat tissue (p < 0.001), being higher in SAT than in VAT (p < 0.001) without gender-specific differences. Hepatic expression of 11beta-HSD1 correlated positively with SAT and VAT, alanine aminotransferase (ALT), and serum glucose and was inversely associated with BMI. 11beta-HSD1 mRNA in VAT correlated positively with insulinemia, ALT, and LDL cholesterol. There were no associations between 11beta-HSD1 mRNA in SAT and the variables analyzed.

Conclusions: 11beta-HSD1 expression is higher in liver in comparison to adipose tissue in obese patients. The observed correlations between hepatic and VAT 11beta-HSD1 expression with dyslipidemia and insulin resistance suggest that this enzyme might have a pathogenic role in obesity and related metabolic disorders.

Citing Articles

Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity.

Zhong C, Li N, Wang S, Li D, Yang Z, Du L Nat Commun. 2024; 15(1):8588.

PMID: 39362888 PMC: 11449908. DOI: 10.1038/s41467-024-52965-4.

Deciphering the role of alternative splicing as a potential regulator in fat-tail development of sheep: a comprehensive RNA-seq based study.

Bakhtiarizadeh M Sci Rep. 2024; 14(1):2361.

PMID: 38287039 PMC: 10825154. DOI: 10.1038/s41598-024-52855-1.

Meta-analysis of RNA-Seq datasets highlights novel genes/pathways involved in fat deposition in fat-tail of sheep.

Hosseini S, Bakhtiarizadeh M, Salehi A Front Vet Sci. 2023; 10:1159921.

PMID: 37252399 PMC: 10213422. DOI: 10.3389/fvets.2023.1159921.

11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases.

Kupczyk D, Studzinska R, Kolodziejska R, Baumgart S, Modrzejewska M, Wozniak A J Clin Med. 2022; 11(20).

PMID: 36294507 PMC: 9605099. DOI: 10.3390/jcm11206190.

11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases.

Kupczyk D, Bilski R, Kozakiewicz M, Studzinska R, Kedziora-Kornatowska K, Kosmalski T Int J Mol Sci. 2022; 23(16).

PMID: 36012251 PMC: 9409048. DOI: 10.3390/ijms23168984.

References

Krozowski Z, Li K, Koyama K, Smith R, Obeyesekere V, Sasano H . The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999; 69(1-6):391-401. DOI: 10.1016/s0960-0760(99)00074-6. View

Paterson J, Seckl J, Mullins J . Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol. 2005; 289(3):R642-52. DOI: 10.1152/ajpregu.00017.2005. View

JeZkova J, Marek J, Prazny M, Krsek M, Malickova K, Rosicka M . [Effect of hypercortisolism on development of atherosclerotic changes in blood vessels]. Vnitr Lek. 2003; 49(8):656-67. View

Gholam P, Flancbaum L, Machan J, Charney D, Kotler D . Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007; 102(2):399-408. DOI: 10.1111/j.1572-0241.2006.01041.x. View

Ricketts M, Verhaeg J, Bujalska I, Howie A, Rainey W, Stewart P . Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998; 83(4):1325-35. DOI: 10.1210/jcem.83.4.4706. View

Freeman L, Hewison M, Hughes S, Evans K, Hardie D, Means T . Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005; 106(6):2042-9. DOI: 10.1182/blood-2005-01-0186. View

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

Morton N, Paterson J, Masuzaki H, Holmes M, Staels B, Fievet C . Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004; 53(4):931-8. DOI: 10.2337/diabetes.53.4.931. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

10.

Reaven G . Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12):1595-607. DOI: 10.2337/diab.37.12.1595. View

11.

Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M, Dutour A . 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006; 14(5):794-8. DOI: 10.1038/oby.2006.92. View

12.

Altuna M, Lelli S, San Martin de Viale L, Damasco M . Effect of stress on hepatic 11beta-hydroxysteroid dehydrogenase activity and its influence on carbohydrate metabolism. Can J Physiol Pharmacol. 2007; 84(10):977-84. DOI: 10.1139/y06-046. View

13.

Paulsen S, Pedersen S, Fisker S, Richelsen B . 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007; 15(8):1954-60. DOI: 10.1038/oby.2007.233. View

14.

Turpeinen U, Markkanen H, Sane T, Hamalainen E . Determination of free tetrahydrocortisol and tetrahydrocortisone ratio in urine by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2006; 66(2):147-59. DOI: 10.1080/00365510500474504. View

15.

Wolf G . Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev. 2002; 60(5 Pt 1):148-51. DOI: 10.1301/00296640260093823. View

16.

Tomlinson J, Bujalska I, Stewart P, Cooper M . The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res. 2001; 26(4):711-22. DOI: 10.3109/07435800009048591. View

17.

Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J . A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001; 294(5549):2166-70. DOI: 10.1126/science.1066285. View

18.

Tomlinson J, Walker E, Bujalska I, Draper N, Lavery G, Cooper M . 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004; 25(5):831-66. DOI: 10.1210/er.2003-0031. View

19.

Holmes M, Kotelevtsev Y, Mullins J, Seckl J . Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol. 2001; 171(1-2):15-20. DOI: 10.1016/s0303-7207(00)00386-5. View

20.

Atanasov A, Odermatt A . Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?. Endocr Metab Immune Disord Drug Targets. 2007; 7(2):125-40. DOI: 10.2174/187153007780832082. View